£2,000 invested in penny share Angle just 3 months ago would now be worth…

Angle (LON:AGL) is a small share that’s skyrocketed in recent weeks. Why does this investor hold the high-risk penny stock?

| More on:
A pastel colored growing graph with rising rocket.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A penny share called Angle (LSE: AGL) has roared back to life at the bottom of my portfolio. I remember it did this at the same time last year, before slumping beneath a £50m market-cap. Must be a new-year optimism thing.

As I write, it’s priced at 16.4p, which is 111% higher than at the start of November. This means a plucky investor who put two grand into this penny stock back then would now be sitting on about £4,220. Nice.

Valued only in the hundreds of pounds though, my holding’s worth well below that. However, I won’t complain, and I’m optimistic the share price could head higher, over time.

What’s the angle?

This small cancer diagnostics company specialises in liquid biopsies — non-invasive blood tests that can detect cancer cells or tumour DNA. These can help doctors diagnose cancer, assess treatments, and monitor to see if the disease has returned. 

Angle’s pioneered the Parsortix liquid biopsy system. This device separates cells and captures circulating tumour cells (CTCs) from blood samples. It’s increasingly being seen as a game-changing technology in the emerging field of personalised cancer care.

There are a few interesting interesting things to note here. Firstly, the company’s CTC-harvesting technology’s patent-protected and already cleared by the FDA for use in breast cancer. So this de-risks the investment case with regard to the company’s core technology (it works).

In 2024, it signed two deals with AstraZeneca and one with Japanese pharma firm Eisai. This is to support clinical trials and cancer drug development.

Angle is also working on next-generation capabilities for an even more comprehensive view of cancer progression. On 29 January, it announced successful results from a new dual workflow, using biotech company Illumina‘s platform. Consequently, the DNA-sequencing giant has assigned its entire European Association for Cancer Research webinar on 6 February to Angle’s findings!

CEO Andrew Newland commented: “We see a substantial opportunity for both Angle and Illumina to work closely together.”

Finally, the global liquid biopsy market’s already large and growing. According to Fortune Business Insights, it’s projected to grow from $9.63bn in 2024 to around $58bn by 2032.

Risks galore

Now, there are also significant risks here. Although it expects 2024 revenue to have increased 31% year on year £2.9m, it’s also guiding for a loss of £14m (down from £20.1m in 2023).

And while the loss-making company holds £12.6m in cash, enough to last until 2026, another share offering remains possible. That would potentially dilute shareholders like myself.

Asymmetric investing opportunity

Still, I’m excited to see what the future brings as Angle pivots from selling instruments to providing services for blue-chip pharma companies like Astra.

According to current forecasts, revenue’s expected to grow 49% in 2025 to £4.3m, then 68% to £7.26m in 2026. However, if cancer trials using its technology advance to larger, late-stage studies, revenue could explode.

Indeed, Angle says that landing a single Phase 3 contract could immediately push the company into cash flow-positive territory.

My thinking here is that I can handle losing a few hundred quid if things turn pear-shaped. But if the firm’s technology’s successfully commercialised, the rewards are potentially very large for this penny stock.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Angle Plc and AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

2 UK shares that could soar if interest rates sprint lower!

The Bank of England's latest meeting has fed speculation of swingeing interest rate cuts. I think these UK shares could…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

My favourite FTSE dividend stock just jumped 17%! So why am I sad?

This investor has mixed feelings today as a quality dividend stock from the FTSE 250 surged higher in his portfolio.…

Read more »

Investing Articles

Here’s why AstraZeneca stock jumped nearly 6% in the FTSE 100 today

FTSE 100 heavyweight AstraZeneca helped propel the blue-chip index to a record high today. Here's what investors were cheering.

Read more »

Closeup of "interest rates" text in a newspaper
Investing Articles

Interest rates fall again! Here are 3 FTSE dividend growth shares to consider buying

As interest on cash savings becomes increasingly less attractive, Paul Summers has been looking at dividend growth shares for passive…

Read more »

Investing Articles

Up 10% today, I think this FTSE 250 growth share could continue to surge!

Babcock International's flying after upgrading its full-year forecasts. I think the FTSE 250 defence share might just be getting started.

Read more »

Investing Articles

The AstraZeneca share price jumps 5% on today’s strong results – but is it too expensive?

Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's biggest company…

Read more »

Investing Articles

Is this my chance to buy Alphabet shares?

A big step up in AI spending at Google has investors nervous, but has it created an opportunity to buy…

Read more »

Senior woman potting plant in garden at home
Investing Articles

£10k in savings? Here’s how an investor could aim for a monthly second income of £1,200

Mark David Hartley considers how investors could build towards an early retirement plan with a second income from a portfolio…

Read more »